5-fluoro-1-(piperidin-4-yl)indoline | 1334123-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-fluoro-1-(piperidin-4-yl)indoline
• 英文别名: 5-fluoro-1-(piperidin-4-yl)-2,3-dihydro-1H-indole；5-fluoro-1-piperidin-4-yl-2,3-dihydroindole
• CAS: 1334123-16-8
• 化学式: C₁₃H₁₇FN₂
• mdl: MFCD28348055
• 分子量: 220.29
• InChiKey: NCTCTTHDGPNVIA-UHFFFAOYSA-N

物化性质

• 沸点：
  358.4±42.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoro-1-(piperidin-4-yl)indoline 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 27.0h， 生成 5-fluoro-1-(piperidin-4-yl)indoline
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075

文献信息

• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。
• [EN] SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINYL-PYRIDAZINYLE SUBSTITUÉ UTILES COMME INHIBITEURS DE SCD 1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2013085957A1

  公开（公告）日：2013-06-13

  The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-吡啶嗪衍生物，包括含有它们的制药组合物以及它们作为SCD1抑制剂的用途，有益于治疗肥胖症、2型糖尿病和其他相关代谢紊乱。
• N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Maruyama Megumi

  公开号：US20120214790A1

  公开（公告）日：2012-08-23

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar 1 and Ar 2 are aryl or heteroaryl; V is nitrogen, or CR 3 ; W 1 is a single bond, —C(O)—, etc.; W 2 is C 1 -alkylene; W 3 is a single bond, methylene, —NH—, —CR 4 ═CR 5 —, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R 1a , R 1b and R 1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C 1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍表现出高效性，并且降低了传统副作用风险，对于除精神分裂症以外的与认知功能障碍相关的中枢神经系统疾病具有显著的效果。公式（1）中的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的基团，在其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a，R1b和R1c分别相同或不同，是氢，羟基，卤素，氰基，C1-6烷基等；或其药学上可接受的盐。
• N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
  申请人：Maruyama Megumi

  公开号：US08541585B2

  公开（公告）日：2013-09-24

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, —C(O)—, etc.; W2 is C1-alkylene; W3 is a single bond, methylene, —NH—, —CR4═CR5—, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，并减少传统的副作用风险，同时对于与精神分裂症不同的认知功能相关的中枢神经系统疾病具有显著的效果。本发明提供了式（1）的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂芳基；V为氮或CR3；W1为单键，-C（O）-等；W2为C1-烷基；W3为单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的一个基团，其中n为0或1；m为0到2；k为1到3；Z为单键，亚甲基，氧等；R1a、R1b和R1c分别为相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药学上可接受的盐。
• US8541585B2
  申请人：——

  公开号：US8541585B2

  公开（公告）日：2013-09-24